Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis

Summary

This is a randomized, double-blind, placebo-controlled, multicenter clinical trial in participants with moderate-to-severe plaque psoriasis .

Timeline

Start

2024-01-31

Primary completion

2024-11-01

Completion

2024-11-01

Publications

• Zhang J, Zhou C, Miao G, Zhang S, Duan X, Wu L, Zhang G, Dang N, Ding Y, Han H, Wei A, Yang B, Li L, Li S, Dai X, Zhang J, Lei T, Yan W, Zhang L, Meng Z, Chen R, Song Q, Wang L, Wang W, Hu X, Xiang Z, Shi Z, Zhang L. Novel TYK2 inhibitor D-2570 in moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled, phase 2 trial. J Am Acad Dermatol. 2026 Jan;94(1):143-150. doi: 10.1016/j.jaad.2025.09.036. Epub 2025 Sep 16.

Drugs

Indications